Prosecution Insights
Last updated: April 19, 2026
Application No. 17/924,877

PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE

Non-Final OA §112
Filed
Nov 11, 2022
Examiner
ANDERSON, REBECCA L
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
VICORE PHARMA AB
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
2y 5m
To Grant
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
749 granted / 1022 resolved
+13.3% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
44 currently pending
Career history
1066
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
17.0%
-23.0% vs TC avg
§102
25.0%
-15.0% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1022 resolved cases

Office Action

§112
DETAILED ACTION Claims 1-14 are currently pending in the instant application. Claim 1 is allowed. Claims 2-10 are objected. Claims 7 and 8 are rejected. Claims 11-14 are withdrawn from consideration as being for non-elected subject matter. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-10 in the reply filed on 22 September 2025 is acknowledged. Allowable Subject Matter Claim 1 is allowed. The closest prior art of record is US2004/0167176. US 2004/0167176 provides processes for preparing the formula I: PNG media_image1.png 216 236 media_image1.png Greyscale , such as seen in example 1, wherein the compound PNG media_image2.png 126 176 media_image2.png Greyscale is prepared, see steps (f) and (g) on page 11 wherein 3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide: PNG media_image3.png 112 172 media_image3.png Greyscale from step (f) was dissolved in pyridine followed by addition of pyrrolidineopyridine and butyl chloroformate. However, the closest prior art does not utilize an acid addition salt of the compound of 3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, nor does the prior art reference provide any direction or motivation to add an additional step of forming an acid addition salt of the compound 3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide before reaction with the formula III. Claim Objections Claims 2-10 are objected to because of the following informalities: Dependent claims 2-10 begin with an “A” and should instead begin with a “The” in reference back to the original “A process” in claim 1. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7 and 8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, claims 7 and 8 recite the limitation “wherein the weak base is” in reference to claim 1. There is insufficient antecedent basis for this limitation in the claim as there is no “a weak base” in claim 1. Claim 6 is the first claim to introduce the limitation of “a weak base” in the removal of Z. It is suggested that claims 7 and 8 be amended to be dependent upon claim 6. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 9 January 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

Nov 11, 2022
Application Filed
Jan 09, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582645
Chemokine CXCR4 Receptor Modulators and Uses Related Thereto
2y 5m to grant Granted Mar 24, 2026
Patent 12570666
FUROINDAZOLE DERIVATIVES
2y 5m to grant Granted Mar 10, 2026
Patent 12565504
SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
2y 5m to grant Granted Mar 03, 2026
Patent 12545649
WDR5-MYC INHIBITORS
2y 5m to grant Granted Feb 10, 2026
Patent 12540141
NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 5m
Median Time to Grant
Low
PTA Risk
Based on 1022 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month